IBECS - Resultado de la búsqueda <página 1>

Revistas incluidas
Proceso de evaluación

IBECS-Express
FAQ

Base de datos :	IBECS
Búsqueda :	"1699-048X" [ISSN]
Referencias encontradas :	2802 [refinar]
Mostrando:	1 .. 10 en el formato [Detallado]

^{página 1 de 281}

^{va a la página}

1 / 2802

IBECS

	selecciona
	para imprimir
	Texto Completo

Id:	-66
Autor:	Pla-Juher, Helena; Pardo, Marta; Izquierdo, Àngel J; Darder, Esther; Carbó, Anna; Munté, Elisabet; Torres-Esquius, Sara; Balmaña, Judith; Lázaro, Concepción; Brunet, Joan M.
Título:	Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study / Riesgo de cáncer de endometrio después de RRSO en portadoras de BRCA 1/2: un estudio de cohorte multicéntrico
Fuente:	Clin. transl. oncol. (Print);26(4):1033-1037, Abr. 2024.
Idioma:	en.
doi:	10.1007/s12094-023-03312-4.
Resumen:	Objective: To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). Methods: The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry. Results: After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93û3.95). Conclusions: In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.(AU)
Descriptores:	carcinoma endometrioide carcinosarcoma histerectomía neoplasias endometriales neoplasias de la mama salpingooforectomía
	-estudios de cohortes mutación tamoxifeno predisposición genética a la enfermedad
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

2 / 2802

IBECS

	selecciona
	para imprimir
	Texto Completo

Id:	-65
Autor:	Ostrowska, Kamila; Niewinski, Patryk; Piotrowski, Igor; Ostapowicz, Julia; Koczot, Sabina; Suchorska, Wiktoria Maria; Golusiński, Paweł; Mateusz Masternak, Michal; Golusiński, Wojciech.
Título:	Senescence in head and neck squamous cell carcinoma: relationship between senescence-associated secretory phenotype (SASP) mRNA expression level and clinicopathological features / Senescencia en el carcinoma de células escamosas de cabeza y cuello: relación entre el nivel de expresión del ARNm del fenotipo secretor asociado a la senescencia (SASP) y las características clínico-patológicas
Fuente:	Clin. transl. oncol. (Print);26(4):1022-1032, Abr. 2024. graf.
Idioma:	en.
doi:	10.1007/s12094-023-03364-6.
Resumen:	Background: Cellular senescence is a state characterized by cell-cycle arrest and apoptotic resistance. Senescence in cancer may be induced by oncogenes or therapy. While cellular senescence might play an important role in protection against cancer development, elevated and uncontrolled senescent cells accumulation may promote carcinogenesis by secreting a collection of pro-inflammatory factors, collectively termed the senescence-associated secretory phenotype (SASP). Material and methods: We determined the gene expression at mRNA level of selected cellular senescence markers (p16 and LMNB1) and SASP factors (IL-6, IL-1b, CXCL-1 and TNF-α) in 72 cancerous tissues and 64 normal tissues obtained from patients with head and neck squamous cell carcinoma (HNSCC) and correlated this data with patients' clinical follow-up. Results: Our results indicate higher levels of selected SASP factors in cancerous compared to normal tissues. We presented the relationship between SASP factors expression at the transcript level and the progression of the disease. Moreover, we proposed CXCL1 as a candidate biomarker differentiating normal tissues from cancerous ones and IL1b expression as a molecular factor related to increased TNM stage. Conclusion: Our primary study indicates that SASP expression may be associated with some clinicopathological features. However, a more detailed study is needed to present specific role of senescence-related mechanism and SASPs especially in tumor therapy response and in relation to the patient's immune system condition.(AU)
Descriptores:	carcinoma de células escamosas de cabeza y cuello senescencia celular/genética senescencia celular neoplasias de cabeza y cuello/genética fenotipo
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

3 / 2802

IBECS

	selecciona
	para imprimir

Id:	-64
Autor:	Cui, Yujun; Liu, Xinzhi; Li, Shuai; Wang, Hongzhi; Xiang, Yirong; Zhang, Yangzi; Song, Maxiaowei; Geng, Jianhao; Liu, Zhiyan; Teng, Huajing.
Título:	The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0 / El ypT puede predecir mejor la eficacia de la quimiorradioterapia neoadyuvante que el grado de regresión tumoral en pacientes con cáncer de recto localmente avanzado diagnosticados ypT1-4N0
Fuente:	Clin. transl. oncol. (Print);26(4):1012-1021, Abr. 2024. graf.
Idioma:	en.
doi:	10.1007/s12094-023-03343-x.
Resumen:	Purpose: This study aimed to assess the impact of ypT stage and tumor regression grade (TRG) on the long-term prognosis of patients with locally advanced rectal cancer (LARC) stage ypT1-4N0 after neoadjuvant chemoradiotherapy (NCRT). Methods: We retrospectively analyzed 585 patients with histologically diagnosed middle-low LARC (cT3-4 or cN + by pelvic MRI) from 2014 to 2019. All patients underwent NCRT, followed by total mesorectal excision. Disease-free survival (DFS) rates were compared among patients with different ypT stages and TRGs by KaplanûMeier survival analysis. The chi-square test was used to analyze the relationship between clinicopathological or therapeutic factors and ypT stage. Results: The median follow‐up was 35.8 months (range 2.8û71.8 months). The 3-year DFS was 79.5%. A better 3-year DFS was achieved in patients with a pathologic complete response (94.0% vs. 74.3%, p < 0.001) and those in the ypT0-2 (86.5% vs. 66.6%, p < 0.001), ypN0 (85.0% vs. 60.2%, p < 0.001), and TRG0 + 1 (83.1% vs. 73.0%, p = 0.004) subgroups. A total of 309 patients (52.8%) achieved stage ypT1-4N0 after surgery. Among these patients, the ypT1-2N0 subgroup achieved a significantly higher 3-year DFS than the ypT3-4N0 subgroup (85.4% vs. 72.8%, p = 0.018); in contrast, the 3-year DFS did not significantly differ between the TRG1 and TRG2 + 3 subgroups (79.9% vs. 81.1%, p = 0.833). In the ypT1-2N0 or ypT3-4N0 subgroup, different TRG had no significant effect on failure patterns. Conclusions: For LARC patients with a ypT1-4N0 status after NCRT, ypT stage may be a more effective predictor of long-term prognosis than TRG.(AU)
Descriptores:	tratamiento neoadyuvante pronóstico estadificación de neoplasias resultado del tratamiento neoplasias colorrectales
	-estudios retrospectivos
Límites:	seres humanos
Responsable:	ES15.1 - BNCS

4 / 2802

IBECS

	selecciona
	para imprimir

Id:	-63
Autor:	Wang, Qi; Zhang, Qiang; Zhu, Jiankang; Li, Linchuan; Zeng, Runzhi; Ding, Huanxin; Li, Zhenmin; Feng, Tianyi; Hao, Ruiqi; Zhang, Guangyong.
Título:	Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors / Nomograma para predecir la supervivencia global después de una gastrectomía curativa utilizando factores inflamatorios, nutricionales y patológicos
Fuente:	Clin. transl. oncol. (Print);26(4):1001-1011, Abr. 2024. ilus.
Idioma:	en.
doi:	10.1007/s12094-023-03340-0.
Resumen:	Purpose: To establish a nomogram for predicting the overall survival (OS) in patients with gastric cancer (GC) based on inflammatory, nutritional and pathological factors. Methods: GC patients underwent curative gastrectomy from January 2012 to June 2017 in our hospital were included, and were classified into training set and validation set with a ratio of 7:3. Then variables associated with OS were analyzed using univariate and multivariate Cox regression analysis. Nomograms predicting OS were built using variables from multivariable Cox models. Finally, KaplanûMeier curve and Log-rank test were also conducted to analyze the 1-yr, 3-yr and 5-yr OS to validate the efficiency of risk stratification of the nomogram. Results: A total of 366 GC patients were included. After univariate and multivariate Cox regression analysis, age (HR = 1.52, 95% CI = 1.01û2.30, P = 0.044), CA50 (HR = 1.90, 95% CI = 1.12û3.21, P = 0.017), PNI (HR = 1.65, 95% CI = 1.13û2.39, P = 0.009), SII (HR = 1.46, 95% CI = 1.03û2.08, P = 0.036), T stage (HR = 2.26, 95% CI = 1.01û5.05, P = 0.048; HR = 7.24, 95% CI = 3.64û14.40, P < 0.001) were independent influencing factors on the survival time of GC patients. Five factors including CEA, prognostic nutritional index (PNI), systemic immune-inflammation index (SII), ln (tumor size), T stage, and N stage were identified and entered the nomogram, which showed good discrimination and calibration in both sets. On internal validation, 1-yr, 3-yr and 5-yr nomogram demonstrated a good discrimination with an area under the ROC curve (AUC) of 0.77, 0.84 and 0.86, respectively. The AUC for 1-yr, 3-yr and 5-yr nomogram in validation set was 0.77, 0.79 and 0.81, respectively. The OS in low risk group of training cohort and validation cohort was significantly higher than that of intermediate risk group and high risk group, respectively...(AU)
Descriptores:	nomogramas gastrectomía neoplasias gástricas/cirugía pronóstico área bajo la curva
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

5 / 2802

IBECS

	selecciona
	para imprimir

Id:	-62
Autor:	Gan, Tian; Long, Yun; Wang, Jingting; Zhang, Hanfei; Liao, Meiyan; An, Wenting.
Título:	Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis / Correlación entre la expresión del antígeno carcinoembrionario (CEA) y las mutaciones de EGFR en el cáncer de pulmón de células no pequeñas: un metanálisis
Fuente:	Clin. transl. oncol. (Print);26(4):991-1000, Abr. 2024. ilus.
Idioma:	en.
doi:	10.1007/s12094-023-03339-7.
Resumen:	Objectives: The purpose of this meta-analysis was to investigate the relationship between serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC). Methods: Databases such as PubMed, Cochrane, EMBASE and Google Scholar were systematically searched to identify studies assessing the association of serum CEA expression with EGFR mutations. Across 19 studies, 4168 patients were included between CEA expression and EGFR mutations odds ratio (OR) conjoint analysis of correlations. Results: Compared with CEA-negative NSCLC, CEA-positive tumors had an increased EGFR mutation rate (OR = 1.85, 95% confidence interval: 1.48û2.32, P < 0.00001). This association was observed in both stage IIIB/IV patients (OR = 1.60, 95% CI: 1.18û2.15, P = 0.002) and stage IûIIIA (OR = 1.67, 95% CI: 1.01û2.77, P = 0.05) patients. In addition, CEA expression was associated with exon 19 (OR = 1.97, 95% CI: 1.25û3.11, P = 0.003) and exon 21 (OR = 1.51, 95% CI: 1.07û2.12, P = 0.02) EGFR mutations. In ADC pathological type had also showed the correlation (OR = 1.84, 95% CI: 1.31û2.57, P = 0.0004). Conclusions: This meta-analysis indicated that serum CEA expression was associated with EGFR mutations in NSCLC patients. The results of this study suggest that CEA level may play a predictive role in the EGFR mutation status of NSCLC patients. Detecting serum CEA expression levels can give a good suggestion to those patients who are confused about whether to undergo EGFR mutation tests. Moreover, it may help better plan of the follow-up treatment.(AU)
Descriptores:	biomarcadores antígeno carcinoembrionario carcinoma de pulmón de células no pequeñas mutación receptores ErbB neoplasias pulmonares
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

6 / 2802

IBECS

	selecciona
	para imprimir

Id:	-61
Autor:	Mestre-Ferrándiz, Jorge; Franch Camino, Blanca; Hidalgo, Álvaro; Llano Núñez-Cortés, Alicia del; Llano Señarís, Juan Ernesto del; Lumbreras, Blanca; Beas Pedraza, David; Nuño-Solinís, Roberto; Paz-Ares, Luis; Ramón y Cajal, Santiago.
Título:	Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain / Análisis colaborativo de expertos de la situación y perspectivas de la implementación de pruebas de biomarcadores en oncología en España
Fuente:	Clin. transl. oncol. (Print);26(4):985-990, Abr. 2024.
Idioma:	en.
doi:	10.1007/s12094-023-03338-8.
Resumen:	Purpose: Biomarkers as screening for precision medicine is a fundamental step. The purpose of this article is twofold. First, to highlight the existing barriers in the implementation of Precision Medicine in Spain, with a special emphasis on barriers in access to the determination of biomarkers. Second, to provide a Roadmap that can help implement Precision Medicine equitably at the national level and optimize the use of biomarkers. Methods: A systematic review of literature (SRL) and a focus group (FG) with multidisciplinary experts has been carried out in 2023. Participants were contacted individually, and discourse analysis was processed anonymously. Results: We carried out a quantitative (SRL) and a qualitative approach (FG). The discourse analysis and roadmap were sent individually to each expert for approval. Conclusions: The potential of Precision Medicine has not been fulfilled in Spain. While several regional initiatives are in place, a national plan or strategy around Precision Medicine and use of biomarkers is lacking. In a general context of rapid progress at a global and European level, including the 2021 Europe's Beating Cancer Plan, it is time to define and implement a National Plan to make the promise come true. While some comparable countries within Europe û such as the UK or France û are mature enough to adopt such strategies, in Spain there is still a long way to go. We consider that the different strands of work outlined in the Roadmap can be used as basis for such purpose.(AU)
Descriptores:	biomarcadores oncología médica medicina de precisión neoplasias/diagnóstico
	-España
Límites:	seres humanos masculino femenino
Tipo de Publicación:	revisión sistemática
Responsable:	ES15.1 - BNCS

7 / 2802

IBECS

	selecciona
	para imprimir

Id:	-60
Autor:	Javaid, Saad; Frasier, Kelly; Chaudhary, Ammad Javaid.
Título:	Impact of obesity on in-hospital mortality and morbidity among patients admitted for antineoplastic chemotherapy: a nationwide analysis / Impacto de la obesidad en la mortalidad y morbilidad hospitalaria entre pacientes ingresados para quimioterapia antineoplásica: un análisis a nivel nacional
Fuente:	Clin. transl. oncol. (Print);26(4):977-984, Abr. 2024. graf.
Idioma:	en.
doi:	10.1007/s12094-023-03335-x.
Resumen:	Background: Obesity is a complex and multifactorial medical condition that can have far reaching consequences on cancer patients, particularly those undergoing treatment such as chemotherapy. Our study focuses to comprehensively explore the various adverse outcomes in obese patients receiving chemotherapy during hospitalization. Methods: The National Inpatient Sample 2020 was used using the ICD-10 codes to identify patients hospitalized with a primary discharge diagnosis of neoplastic chemotherapy with or without a secondary diagnosis of obesity. Statistical analysis using Stata software was done, and primary and secondary outcomes were obtained after adjusting for confounders using multivariate regression analysis. Results: Mortality was similar in both obese and non-obese patients. Length of stay and total hospitalization charges were increased in obese patients. Obese patients had higher odds of developing acute respiratory failure and were more likely to require non-invasive and invasive mechanical ventilation. Conclusion: Our study concluded that obesity could be considered an independent predictor of worse outcomes in patients admitted for neoplastic chemotherapy. Notably, addressing obesity could help to improve the efficacy of treatment for cancer patients while simultaneously reducing any negative consequences associated with being obese.(AU)
Descriptores:	obesidad farmacoterapia hospitalización mortalidad hospitalaria antineoplásicos/efectos adversos neoplasias/complicaciones duración de estancia hospitalaria
	-Estados Unidos
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

8 / 2802

IBECS

	selecciona
	para imprimir

Id:	-59
Autor:	Huang, Huimei; Zeng, Shiying; Tang, Xiaojun; Yang, Qian; Qin, Yuexiang; Tang, Qinglai; Yin, Danhui; Li, Shisheng; Zhu, Gangcai.
Título:	The prognosis and treatment of newly diagnosed bone metastasis of head and neck squamous cell cancer: an analysis of racial disparity / El pronóstico y el tratamiento de las metástasis óseas recién diagnosticadas de cáncer de células escamosas de cabeza y cuello: un análisis de la disparidad racial
Fuente:	Clin. transl. oncol. (Print);26(4):966-976, Abr. 2024. ilus.
Idioma:	en.
doi:	10.1007/s12094-023-03327-x.
Resumen:	Objective: There is a lack of research investigating racial disparity in newly diagnosed head and neck squamous cell carcinoma with isolated bone metastases (HNSCC-BM). This study aims to investigate the clinical characteristics and prognostic factors in HNSCC-BM patients from different racial backgrounds to aid clinical decision making and management. Methods: We retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database for 345 cases of HNSCC-BM that were diagnosed between 2010 and 2017. Survival was compared using univariate and multivariate Cox proportional hazards models, KaplanûMeier analysis, and log-rank tests. We also used propensity score matching to adjust for confounders. Results: In white patients, those who were over 40 years of age had a significantly shorter survival (HR, 4.49; 95% CI 1.03û19.56; P < 0.05). Female black patients were found to survive longer compared to male patients (HR, 0.34; 95% CI 0.15û0.76; P < 0.01). Single (never married) Asians had shorter survival than married Asians (HR, 4.68; 95% CI 1.34û16.41; P < 0.05). In all three racial groups, patients who received radiotherapy in addition to chemotherapy did not survive longer than those receiving chemotherapy (P > 0.05). In Asian patients, those who underwent surgery at the primary site combined with chemoradiotherapy had significantly better survival outcomes than those who received chemoradiotherapy (HR: 0.10, 95% CI 0.01û0.88; P = 0.01). Conclusion: Prognostic factors differ between HNSCC-BM patients from different racial backgrounds.(AU)
Descriptores:	metástasis neoplásica carcinoma de células escamosas de cabeza y cuello pronóstico supervivientes de cáncer
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

9 / 2802

IBECS

	selecciona
	para imprimir

Id:	-58
Autor:	Lin, Miaomiao; Xiao, Yanyi; Dai, Yile; Mao, Yefan; Xu, Liming; Zhang, Qiyu; Chen, Zhe.
Título:	Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mTOR signaling pathway / La cloroxina inhibe la progresión del cáncer de páncreas mediante la antagonización dirigida de la vía de señalización PI3K/AKT/mTOR
Fuente:	Clin. transl. oncol. (Print);26(4):951-965, Abr. 2024. graf.
Idioma:	en.
doi:	10.1007/s12094-023-03328-w.
Resumen:	Background: Patients with pancreatic cancer have a dismal prognosis due to tumor cell infiltration and metastasis. Many reports have documented that EMT and PI3KûAKTûmTOR axis control pancreatic cancer cell infiltration and metastasis. Chloroxine is an artificially synthesized antibacterial compound that demonstrated anti-pancreatic cancer effects in our previous drug-screening trial. We have explored the impact of chloroxine on pancreatic cancer growth, infiltration, migration, and apoptosis. Methods: The proliferation of pancreatic cancer cell lines (PCCs) treated with chloroxine was assessed through real-time cell analysis (RTCA), colony formation assay, CCK-8 assay, as well as immunofluorescence. Chloroxine effects on the infiltrative and migratory capacities of PCCs were assessed via Transwell invasion and scratch experiments. To assess the contents of EMT- and apoptosis-associated proteins in tumor cells, we adopted Western immunoblotting as well as immunofluorescence assays, and flow cytometry to determine chloroxine effects on PCCs apoptosis. The in vivo chloroxine antineoplastic effects were explored in nude mice xenografts. Results: Chloroxine repressed pancreatic cancer cell growth, migration, and infiltration in vitro, as well as in vivo, and stimulated apoptosis of the PCCs. Chloroxine appeared to inhibit PCC growth by Ki67 downregulation; this targeted and inhibited aberrant stimulation of the PI3KûAKTûmTOR signaling cascade, triggered apoptosis in PCC via mitochondria-dependent apoptosis, and modulated the EMT to inhibit PCC infiltration and migration. Conclusions: Chloroxine targeted and inhibited the PI3KûAKTûmTOR cascade to repress PCCs growth, migration, as well as invasion, and triggered cellular apoptosis. Therefore, chloroxine may constitute a potential antineoplastic drug for the treatment of pancreatic cancer.(AU)
Descriptores:	neoplasias pancreáticas carcinoma ductal pancreático antineoplásicos cloroquinolinoles/farmacocinética cloroquinolinoles/uso terapéutico proteínas protooncogénicas c-akt/metabolismo
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

10 / 2802

IBECS

	selecciona
	para imprimir

Id:	-57
Autor:	Zhuang, Xujie; Liu, Bo; Long, Junqi; Wang, Huina; Yu, Jiangyong; Ji, Xinchan; Li, Jinmeng; Zhu, Nian; Li, Lujia; Chen, Yuhaoran.
Título:	Machine-learning-based classification of diffuse large B-cell lymphoma patients by a 7-mRNA signature enriched with immune infiltration and cell cycle / Clasificación basada en aprendizaje automático de pacientes con linfoma difuso de células B grandes mediante una firma de 7 ARNm enriquecida con infiltración inmune y ciclo celular
Fuente:	Clin. transl. oncol. (Print);26(4):936-950, Abr. 2024. ilus, graf.
Idioma:	en.
doi:	10.1007/s12094-023-03326-y.
Resumen:	Background: Diffuse large B-cell lymphoma (DLBCL) exhibits remarkable heterogeneity but still remains undiagnosed in identifying the subpopulation of DLBCL to predict the prognosis and guide clinical treatment. Methods: Molecular subgroups were identified in gene expression data from GSE10846 by a consensus clustering algorithm. And gene set enrichment analysis, immune infiltration, and the proposed cell cycle algorithm were applied to explore the biological functions of different subtypes. Meanwhile, univariate and multivariate Cox regression analyses were used to evaluate independent prognostic factors of DLBCL. Finally, the prognostic model, including some key genes screened by Lasso regression, Random Forest algorithm, and point-biserial correlation, was constructed by an optimal classifier from seven machine learning algorithms and validated by another three external datasets (GSE34171, GSE87371, GSE31312). Results: Comprehensive genomic analysis of 1,143 DLBCL samples identify 2 molecularly, prognostically relevant subtypes: immune-enriched (IME) and cell-cycle-enriched (CCE). Then a new predictive model including seven key genes (SERPING1, TIMP2, NME1, DCTPP1, RFC4, POLE2, and SNRPD1) was developed with high prediction accuracy (88.6%) and strong predictive power (AUC = 0.973) based on the Support Vector Machine (SVM) algorithm in 414 patients from GSE10846. The predictive power was similar in another three testing sets (HR > 1.400, p < 0.05). Conclusion: This model could evaluate survival independently with strong predictive power compared with other clinical risk factors. Our study constructed a reliable model to predict two new subtypes of DLBCL patients, which could guide the implementation of individualized treatment.(AU)
Descriptores:	linfoma de células B grandes difuso pronóstico aprendizaje automático ciclo celular/genética algoritmos secuenciación del genoma completo
Límites:	seres humanos masculino femenino
Responsable:	ES15.1 - BNCS

^{página 1 de 281}

^{va a la página}

Refinar la búsqueda

Base de datos : IBECS

Formulario avanzado

Buscar por : Formulario libre Formulario básico

	Buscar	en el campo
1
2
3

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud